Diagnosis, assessment, and phenotyping of COPD: beyond FEV1

2.50
Hdl Handle:
http://hdl.handle.net/11287/600364
Title:
Diagnosis, assessment, and phenotyping of COPD: beyond FEV1
Authors:
Finch, D; Lange, P; Halpin, David M; O’Donnell, D; MacNee, W
Abstract:
COPD is now widely recognized as a complex heterogeneous syndrome, having both pulmonary and extrapulmonary features. In clinical practice, the diagnosis of COPD is based on the presence of chronic airflow limitation, as assessed by post-bronchodilator spirometry. The severity of the airflow limitation, as measured by percent predicted FEV1, provides important information to the physician to enable optimization of management. However, in order to accurately assess the complexity of COPD, there need to be other measures made beyond FEV1. At present, there is a lack of reliable and simple blood biomarkers to confirm and further assess the diagnosis of COPD. However, it is possible to identify patients who display different phenotypic characteristics of COPD that relate to clinically relevant outcomes. Currently, validated phenotypes of COPD include alpha-1 antitrypsin deficiency, and “frequent exacerbators”. Recently, a definition and assessment of a new phenotype comprising patients with overlapping features of asthma and COPD has been suggested and is known as “asthma COPD overlap syndrome”. Several other phenotypes have been proposed, but require validation against clinical outcomes. Defining phenotypes requires the assessment of multiple factors indicating disease severity, its impact, and its activity. Recognition and validation of COPD phenotypes has an important role to play in the selection of evidence-based targeted therapy in the future management of COPD, but regardless of the diagnostic terms, patients with COPD should be assessed and treated according to their individual treatable characteristics.
Citation:
Diagnosis, assessment, and phenotyping of COPD: beyond FEV1 2016:3 International Journal of Chronic Obstructive Pulmonary Disease
Publisher:
Dove Press
Journal:
International Journal of Chronic Obstructive Pulmonary Disease
Issue Date:
18-Feb-2016
URI:
http://hdl.handle.net/11287/600364
DOI:
10.2147/COPD.S85976
PubMed ID:
26937185
Additional Links:
https://www.dovepress.com/diagnosis-assessment-and-phenotyping-of-copd-beyond-fev1-peer-reviewed-article-COPD
Note:
The article is freely available via Open Access. Click on the 'Additional Link' above to access the full-text from the publisher's site.
Type:
Journal Article
Language:
en
ISSN:
1178-2005
Appears in Collections:
Respiratory Medicine; 2016 RD&E publications

Full metadata record

DC FieldValue Language
dc.contributor.authorFinch, Den
dc.contributor.authorLange, Pen
dc.contributor.authorHalpin, David Men
dc.contributor.authorO’Donnell, Den
dc.contributor.authorMacNee, Wen
dc.date.accessioned2016-02-29T10:36:19Zen
dc.date.available2016-02-29T10:36:19Zen
dc.date.issued2016-02-18en
dc.identifier.citationDiagnosis, assessment, and phenotyping of COPD: beyond FEV1 2016:3 International Journal of Chronic Obstructive Pulmonary Diseaseen
dc.identifier.issn1178-2005en
dc.identifier.pmid26937185en
dc.identifier.doi10.2147/COPD.S85976en
dc.identifier.urihttp://hdl.handle.net/11287/600364en
dc.description.abstractCOPD is now widely recognized as a complex heterogeneous syndrome, having both pulmonary and extrapulmonary features. In clinical practice, the diagnosis of COPD is based on the presence of chronic airflow limitation, as assessed by post-bronchodilator spirometry. The severity of the airflow limitation, as measured by percent predicted FEV1, provides important information to the physician to enable optimization of management. However, in order to accurately assess the complexity of COPD, there need to be other measures made beyond FEV1. At present, there is a lack of reliable and simple blood biomarkers to confirm and further assess the diagnosis of COPD. However, it is possible to identify patients who display different phenotypic characteristics of COPD that relate to clinically relevant outcomes. Currently, validated phenotypes of COPD include alpha-1 antitrypsin deficiency, and “frequent exacerbators”. Recently, a definition and assessment of a new phenotype comprising patients with overlapping features of asthma and COPD has been suggested and is known as “asthma COPD overlap syndrome”. Several other phenotypes have been proposed, but require validation against clinical outcomes. Defining phenotypes requires the assessment of multiple factors indicating disease severity, its impact, and its activity. Recognition and validation of COPD phenotypes has an important role to play in the selection of evidence-based targeted therapy in the future management of COPD, but regardless of the diagnostic terms, patients with COPD should be assessed and treated according to their individual treatable characteristics.en
dc.language.isoenen
dc.publisherDove Pressen
dc.relation.urlhttps://www.dovepress.com/diagnosis-assessment-and-phenotyping-of-copd-beyond-fev1-peer-reviewed-article-COPDen
dc.rightsArchived with thanks to International Journal of Chronic Obstructive Pulmonary Disease. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.en
dc.subjectWessex Classification Subject Headings::Respiratory medicineen
dc.titleDiagnosis, assessment, and phenotyping of COPD: beyond FEV1en
dc.typeJournal Articleen
dc.identifier.journalInternational Journal of Chronic Obstructive Pulmonary Diseaseen
dc.description.noteThe article is freely available via Open Access. Click on the 'Additional Link' above to access the full-text from the publisher's site.en
dc.type.versionPublisheden

Related articles on PubMed

All Items in RD&E Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.